SCHEMBL9516205

SCHEMBL9516205

CCOC(=O)C(Cc1ccccc1)N1CCOCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
LMNA P02545 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
ALDH1A1 P00352 2/20 0.50
MAPT P10636 2/20 0.50
HPGD P15428 1/20 0.50
RAB9A P51151 1/20 0.50
HSD17B10 Q99714 2/20 0.49
PPARG P37231 1/20 0.48
PPARA Q07869 1/20 0.48
MEN1 O00255 3/20 0.47
MMP8 P22894 2/20 0.47
POLB P06746 3/20 0.46
MAPK1 P28482 1/20 0.46
TSHR P16473 1/20 0.46
KDM4E B2RXH2 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
PTPN7 P35236 1/20 0.44
RECQL P46063 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30842270 0.86 HSD17B10 (0.51) KMT2ALMNANPSR1ALDH1A1MAPT
SCHEMBL22916606 0.86 RAB9A (0.56) KMT2ALMNAALDH1A1MAPTHPGD
SCHEMBL9518202 0.85 IDO1 (0.54) KMT2ALMNAMAPTRAB9AHSD17B10
SCHEMBL19026256 0.84 LMNA (0.48) KMT2ALMNANPSR1ALDH1A1MAPT
SCHEMBL9309772 0.84 SLC6A4 (0.50) KMT2ALMNAMAPTHSD17B10MEN1
SCHEMBL28279760 0.83 HSD17B10 (0.54) KMT2ALMNANPSR1ALDH1A1MAPT
SCHEMBL7280926 0.83 LMNA (0.68) KMT2ALMNANPSR1ALDH1A1MAPT
SCHEMBL9516925 0.83 LMNA (0.68) KMT2ALMNANPSR1ALDH1A1MAPT
SCHEMBL9308762 0.83 ALDH1A1 (0.53) KMT2ALMNAALDH1A1MAPTMEN1
SCHEMBL15063194 0.78 TSHR (0.62) KMT2ALMNANPSR1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210023034-A1 PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2021-01-28 US disclosed
EP-0266950-B1 Nor-statine and nor-cyclostatine polypeptides PFIZER (US) 1993-12-29 EP disclosed
US-5034376-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1991-07-23 US disclosed
US-4935405-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1990-06-19 US disclosed
US-4814342-A Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1989-03-21 US disclosed
EP-0266950-A2 Nor-statine and nor-cyclostatine polypeptides PFIZER INC. (US) 1988-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210023034-A1 PHENYLALANINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCERS IL4I1, PAH, IL4 KMT2A 629/4885LMNA 4429/4885NPSR1 1384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.